Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two hormonal pathways involved in appetite regulation and blood sugar control
Severe or persistent symptoms warrant medical evaluation, but the typical experience is discomfort that fades rather than worsens over time
Here are some tips on how to monitor and report side effects effectively: Keep a Symptom Diary: Write down any skin changes you notice, including when they occur, how long they last, and any factors that might have triggered them
Key monitoring recommendations include: Baseline testosterone assessment for men with symptoms of hypogonadism before starting semaglutide Evaluation of new or worsening symptoms during treatment with comprehensive metabolic and hormonal testing as clinically indicated Continued monitoring for patients on testosterone replacement therapy according to standard guidelines Consideration of nutritional status, sleep quality, and psychological factors when interpreting symptoms Referral to endocrinology for complex cases or when hormonal abnormalities are identified Patients should be counseled that significant weight loss itself typically improves testosterone levels in men with obesity and that any concerning symptoms should be reported promptly for appropriate evaluation
GIP works in conjunction with GLP-1 to enhance insulin secretion when blood sugar increases, aiding in the reduction of it back to baseline
For patients with well-controlled Graves disease who are euthyroid on antithyroid medications or following definitive treatment (radioactive iodine or thyroidectomy), tirzepatide may be considered if there are appropriate indications such as type 2 diabetes or obesity (BMI 30 kg/m or 27 kg/m with weight-related comorbidities)
